This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
AZNPositive Net Change BAYRYNegative Net Change EDITNegative Net Change ALLONegative Net Change
biotechnology biotechs crispr earnings medical pharmaceuticals
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
RDYNegative Net Change BAYRYNegative Net Change ALLONegative Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
by Zacks Equity Research
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
SNYNo Net Change BEAMNegative Net Change ADMANegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
by Zacks Equity Research
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
RHHBYPositive Net Change BMYNegative Net Change NVONegative Net Change PRTANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
BAYRYNegative Net Change BEAMNegative Net Change PCRXPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
BAYRYNegative Net Change BEAMNegative Net Change ADMANegative Net Change RCKTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Best Momentum Stocks to Buy for May 9th
by Zacks Equity Research
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
BCRXNegative Net Change RMBSNegative Net Change WYYNegative Net Change
biotechnology
Limbach (LMB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
LMBPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
by Ekta Bagri
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
GRFSPositive Net Change ADMANegative Net Change TAKPositive Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
BAYRYNegative Net Change BEAMNegative Net Change CPRXNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
by Zacks Equity Research
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
BAYRYNegative Net Change BEAMNegative Net Change ADMANegative Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
by Zacks Equity Research
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
BAYRYNegative Net Change BEAMNegative Net Change ADMANegative Net Change ACADNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cytokinetics Q1 Earnings Beat, Aficamten Target Action Date Extended
by Zacks Equity Research
CYTK reports narrower-than-expected Q1 loss. However, the target action date for aficamten in obstructive HCM has been extended by the FDA to provide time for reviewing a REMS submission made at the agency's request.
SNYNo Net Change BAYRYNegative Net Change CYTKPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
by Zacks Equity Research
DNLI reports a wider-than-expected loss for the first quarter of 2025. Denali submits a BLA for tividenofusp alfa under the FDA???s accelerated approval pathway based on data from the phase I/II study in participants with Hunter syndrome.
SNYNo Net Change BIIBNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
REGNPositive Net Change BAYRYNegative Net Change RARENegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
NVONegative Net Change LLYPositive Net Change BAYRYNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
by Zacks Equity Research
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
BAYRYNegative Net Change BEAMNegative Net Change ADMANegative Net Change KRYSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
BAYRYNegative Net Change BEAMNegative Net Change ZTSNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
BAYRYNegative Net Change BEAMNegative Net Change ADMANegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
by Ahan Chakraborty
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
NVONegative Net Change PCRXPositive Net Change RARENegative Net Change ACADNegative Net Change DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
by Santanu Roy
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
KONegative Net Change DGXNegative Net Change STZNegative Net Change DAVENegative Net Change LNGPositive Net Change MNSTNegative Net Change ROLNegative Net Change IPINegative Net Change ADMANegative Net Change NOBLNegative Net Change LMBPositive Net Change PRMBNegative Net Change
agriculture biotechnology business-services consumer-staples medical oil-energy
Viatris Q1 Earnings Release: What's in Store for the Stock?
by Zacks Equity Research
VTRS' Q1 results are likely to gain from new product launches in all major geographies.
VRTXNegative Net Change ANIPNegative Net Change DNLINegative Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
by Zacks Equity Research
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
TEVAPositive Net Change BEAMNegative Net Change FOLDPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
by Zacks Equity Research
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
BAYRYNegative Net Change BEAMNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y
by Zacks Equity Research
ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals